Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

Literature DB >> 7793893

Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

Abstract

The efficacy of D0870 was studied in a murine model of systemic histoplasmosis and was compared with that of fluconazole. All regimens of D0870 (1 or 10 mg/kg of body weight given daily or 1, 10, or 100 mg/kg given every other day) and 100 mg of fluconazole per kg given daily provided complete protection from lethality. Comparison of the number of viable Histoplasma capsulatum yeasts remaining in the spleen or liver indicated that D0870 was superior to fluconazole in clearing and curing infection. D0870 was 10- to 100-fold more efficacious than fluconazole in the treatment of experimental histoplasmosis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 7793893 PMCID： PMC162626 DOI： 10.1128/AAC.39.3.778

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

1. In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors: G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal: Antimicrob Agents Chemother Date: 1990-04 Impact factor: 5.191

Review 2. Histoplasmosis and AIDS.

Authors: J R Graybill
Journal: J Infect Dis Date: 1988-09 Impact factor: 5.226

3. Treatment of murine histoplasmosis with UK 49,858 (fluconazole).

Authors: J R Graybill; E Palou; J Ahrens
Journal: Am Rev Respir Dis Date: 1986-10

4. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group.

Authors: M Diaz; R Negroni; F Montero-Gei; L G Castro; S A Sampaio; D Borelli; A Restrepo; L Franco; J L Bran; E G Arathoon
Journal: Clin Infect Dis Date: 1992-03 Impact factor: 9.079

5. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.

Authors: W E Dismukes; R W Bradsher; G C Cloud; C A Kauffman; S W Chapman; R B George; D A Stevens; W M Girard; M S Saag; C Bowles-Patton
Journal: Am J Med Date: 1992-11 Impact factor: 4.965

6. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors: T Peng; J N Galgiani
Journal: Antimicrob Agents Chemother Date: 1993-10 Impact factor: 5.191

7. Induction of stress protein synthesis in Histoplasma capsulatum by heat, low pH and hydrogen peroxide.

Authors: K Kamei; E Brummer; K V Clemons; D A Stevens
Journal: J Med Vet Mycol Date: 1992

8. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

Authors: J S Hostetler; K V Clemons; L H Hanson; D A Stevens
Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191

4. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

Authors: P Connolly; J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal: Antimicrob Agents Chemother Date: 1999-02 Impact factor: 5.191

4 in total

Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

1. In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Review 2. Histoplasmosis and AIDS.

3. Treatment of murine histoplasmosis with UK 49,858 (fluconazole).

4. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group.

5. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.

6. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

7. Induction of stress protein synthesis in Histoplasma capsulatum by heat, low pH and hydrogen peroxide.

8. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

9. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.

10. Activities of the triazole D0870 in vitro and against murine blastomycosis.

Review 1. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

2. Efficacy of D0870 treatment of experimental Candida vaginitis.

3. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

4. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.